Olivier Hantz, Jean-Louis Kraus and Fabien Zoulim Pages 503 - 523 ( 21 )
Antiviral therapy of chronic hepatitis B remains a major clinical problem worldwide. The design of new nucleoside analogs that inhibit hepatitis B virus (HBV) replication allowed their evaluation in in vitro and in vivo experimental models of HBV infection. This research has led to the discovery of the anti-HBV activity of lamivudine and its approval for the therapy of chronic hepatitis B. However, due to the development of viral resistance, strategies based on the combination of new inhibitors of HBV replication with immune modulatory approaches are urgently required.
Hepatitis B Virus Inhibitors, Antiviral Therapy, Anti HBV, Infection, Lamivudine, activity, Drug Design, Nucleoside analogs, Pronucleotide, Polyazamacrocycle derivatives, Miscellaneous compounds, Pyrimidine, Purine, FMAU 4, deoxyguanosine 2 CDG, DHBV, Pronucleotides, glycosylation Inhibitors, Antisense Oligonucleotides m RNA, Translation, Phenylporpenamide, Screening, Transfected Cell LInes, CCC DNA, DMEM RPMI, Cytootxicity, famciclovir, Baculoviruses infected Hepatoma, Viral Polymerase Assay, Priming Reverse Transcriptase, Duck Model Infection, Carbocyclic, deoxyguanosine CDG, Ganciclovir Penciclovir, Adefovir Dipivoxil, Thymidine, cytidine, Drug Therapy, Lobucavir, Entecavir
INSERM Unit 271, 151cours Albert Thomas, 69003 Lyon, France